UP Manila seeks partners to commercialize 'game changer' ampalaya tablet. Photo from Pexels

Rowegie Abanto

ABS-CBN News

<div><img src="https://od2-image-api.abs-cbn.com/prod/editorImage/1728436732235pexels-tamanna-rumee-52377920-8793858.jpg" style="width:900px" class="fr-fic fr-dib"/>UP Manila seeks partners to commercialize &#x27;game changer&#x27; ampalaya tablet. Photo from Pexels </div>MANILA — The University of the Philippines Manila is seeking partners to commercialize and market its ampalaya medicine tablet, developed after years of clinical trials and found to be a promising alternative that could complement treatments for managing Type 2 diabetes in millions of Filipinos. UP Manila&#x27;s Institute of Herbal Medicine (IHM) announced last week the development of its &quot;game changer&quot; ampalaya tablet that completed Phase 3 clinical trials and was proven to lower blood sugar levels.<div><a href="https://news.abs-cbn.com/lifestyle/health-wellness/2024/10/2/up-researchers-ampalaya-medicine-tablet-for-type-2-diabetes-shows-promise-1343" id="isPasted">READ: UP researchers&#x27; ampalaya medicine tablet for Type 2 diabetes shows promise</a></div>Dr. Cecilia C. Maramba-Lazarte, director of IHM, said Wednesday that the institute was still attracting pharmaceutical companies and entrepreneurs to license the ampalaya tablet for manufacturing and production.<div></div>However, Maramba-Lazarte noted in an email with ABS-CBN News that they were &quot;getting a lot of inquiries from interested parties&quot; and expressed hope for &quot;more good news about it soon.&quot;<div>She added that the registration of the ampalaya medicine tablet before the Food and Drug Administration could take about a year. </div><div>&#x27;AFFORDABLE OPTION&#x27;</div>While the ampalaya tablet is not yet available commercially, Marinela J. Gravidez of UP Manila&#x27;s Technology Licensing and Business Development said it could be &quot;an affordable option for consumers, making it an attractive product in the market.&quot;<span id="isPasted" style="color:rgb(65, 65, 65);letter-spacing:normal;orphans:2;text-align:left;text-indent:0px;text-transform:none;widows:2;word-spacing:0px;-webkit-text-stroke-width:0px;white-space:normal;background-color:rgb(255, 255, 255);text-decoration-thickness:initial;text-decoration-style:initial;text-decoration-color:initial;display:inline !important;float:none">Gravidez said that the business development unit was actively seeking licensees to bridge the gap between research and commercialization.The ampalaya medicine tablet, derived from powdered ampalaya leaves, is stable at room temperature for at least one and a half years, according to Daisy-Mae Bagaoisan, a registered pharmacist and research assistant professor at IHM.<div>Bagaoisan noted that the ampalaya pill was formulated according to World Health Organization guidelines. </div><div>It is &quot;very safe with no known side effects,&quot; she said.</div>Diabetes is <a href="https://news.abs-cbn.com/spotlight/12/19/23/heart-attack-diabetes-cancer-among-top-causes-of-death-in-ph-doh">one of the leading causes of death</a> in the Philippines, where the cost of medicines is often prohibitive for the poor. Earlier this year, the Bureau of Internal Revenue moved to exempt <a href="https://news.abs-cbn.com/business/2024/1/31/bir-exempts-21-medicines-for-cancer-diabetes-hypertension-from-vat-911">21 new medicines</a> from value-added tax, including those for diabetes.For those interested in licensing and manufacturing the ampalaya medicine tablet, please contact Marinela J. Gravidez.<div>Tel. No.: +63(2) 8814 1293 Website: http://ttbdo.upm.edu.ph/</div>

The University of the Philippines Manila is seeking partners to commercialize its ampalaya medicine tablet found to be a promising alternative that could complement treatments for managing diabetes.

The University of the Philippines Manila is seeking partners to commercialize its ampalaya medicine tablet found to be a promising alternative that could complement treatments for managing diabetes.

UP Manila seeks partners to commercialize ampalaya pill for diabetes | ABS-CBN

Entertainment

News

Metro.Style

Sports

More

Wellness

UP Manila seeks partners to commercialize ampalaya pill for diabetes

UP Manila seeks partners to commercialize ampalaya pill for diabetes

Rowegie Abanto,

ABS-CBN News

Published Oct 09, 2024 09:54 AM PHT

|

Updated Oct 09, 2024 12:13 PM PHT

Read More:

ampalaya tablet

ampalaya

UP Manila

diabetes

type 2 diabetes

medicine

ABSNews

. ANC promo

ABS-CBN is the leading media and entertainment company in the Philippines, offering quality content across TV, radio, digital, and film. Committed to public service and promoting Filipino values, ABS-CBN continues to inspire and connect audiences worldwide.

Corporate

Investors

Governance

International Distribution

Corporate

Governance

Investors

International Distribution

NPC Seal of Registration

Privacy Policy

Terms of Service

Advertise with Us

© 2024 ABS-CBN Corporation. All Rights Reserved.

NPC Seal of Registration

Advertise with Us

Privacy Policy

Terms of Service

© 2024 ABS-CBN Corporation. All Rights Reserved.